US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0642-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0641-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0640-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0639-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0638-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0637-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0636-2026
Class II · Moderate risk Ongoing

Med Pride

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0635-2026
Class II · Moderate risk Ongoing

Cura Hongos

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0634-2026
Class II · Moderate risk Ongoing

Rapidol

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0633-2026
Class II · Moderate risk Ongoing

Lil Drug Store

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0632-2026
Class II · Moderate risk Ongoing

Circle K

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0631-2026
Class II · Moderate risk Ongoing

Lucky Super Soft

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0630-2026
Class II · Moderate risk Ongoing

Lucky Super Soft

Reason CGMP Deviations; deficiencies observed during FDA inspection

Dabur India Limited D-0629-2026
Class III · Low risk Ongoing

Fexofenadine Hydrochloride Tablets

Reason Failed Impurities/Degradation Specifications

Sun Pharmaceutical Industries INC NDC 66336-561-30 D-0654-2026
Class III · Low risk Ongoing

Focalin XR

Reason Labeling: Incorrect or Missing Lot and/or Exp Date

Sandoz Inc D-0608-2026
Class II · Moderate risk Ongoing

Minocycline Hydrochloride Extended-Release Tablets

Reason Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis

Ascend Laboratories, LLC D-0597-2026